彭布罗利珠单抗
医学
肺癌
肿瘤科
化疗
成本效益
内科学
生活质量(医疗保健)
PD-L1
质量调整寿命年
癌症
免疫疗法
风险分析(工程)
护理部
作者
Min Huang,Gilberto Lopes,Ralph P. Insinga,Thomas Burke,Flavia Ejzykowicz,Ying Zhang,Josephine Feliciano
出处
期刊:Immunotherapy
[Future Medicine]
日期:2019-12-01
卷期号:11 (17): 1463-1478
被引量:41
标识
DOI:10.2217/imt-2019-0178
摘要
Aim: This analysis aimed to evaluate the cost-effectiveness of pembrolizumab monotherapy as first-line treatment in advanced non-small-cell lung cancer patients with a programmed death ligand 1 (PD-L1) tumor proportion score ≥1% from a US payer perspective. Materials & methods: A partitioned survival model was developed using efficacy and safety data from the KEYNOTE-042 trial and projected over 20 years. Costs accounted for treatment, toxicity and disease management. Quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios were reported. Results: Pembrolizumab resulted in an expected gain of 0.60 life years and 0.49 QALYs compared with platinum-based chemotherapy. The incremental cost-effectiveness ratio was US$130,155/QALY. Conclusion: Pembrolizumab is projected to be cost-effective compared with platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer with PD-L1 tumor proportion score ≥1%.
科研通智能强力驱动
Strongly Powered by AbleSci AI